APA (7th ed.) Citation

Munjal, S., Brand-Schieber, E., Allenby, K., Spierings, E. L., Cady, R. K., & Rapoport, A. M. (2017). A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Journal of headache and pain, 18(1), 31-8. https://doi.org/10.1186/s10194-017-0740-3

Chicago Style (17th ed.) Citation

Munjal, Sagar, Elimor Brand-Schieber, Kent Allenby, Egilius L.H Spierings, Roger K. Cady, and Alan M. Rapoport. "A Multicenter, Open-label, Long-term Safety and Tolerability Study of DFN-02, an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM, for the Acute Treatment of Episodic Migraine." Journal of Headache and Pain 18, no. 1 (2017): 31-8. https://doi.org/10.1186/s10194-017-0740-3.

MLA (9th ed.) Citation

Munjal, Sagar, et al. "A Multicenter, Open-label, Long-term Safety and Tolerability Study of DFN-02, an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM, for the Acute Treatment of Episodic Migraine." Journal of Headache and Pain, vol. 18, no. 1, 2017, pp. 31-8, https://doi.org/10.1186/s10194-017-0740-3.